Global RNA Therapeutics and Vaccines Market Growth 2023-2029
The report requires updating with new data and is sent in 48 hours after order is placed.
According to our LPI (LP Information) latest study, the global RNA Therapeutics and Vaccines market size was valued at US$ million in 2022. With growing demand in downstream market, the RNA Therapeutics and Vaccines is forecast to a readjusted size of US$ million by 2029 with a CAGR of % during review period.
The research report highlights the growth potential of the global RNA Therapeutics and Vaccines market. RNA Therapeutics and Vaccines are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of RNA Therapeutics and Vaccines. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the RNA Therapeutics and Vaccines market.
RNA therapeutics and vaccines represent a groundbreaking approach to medical interventions that leverage the unique properties of ribonucleic acid (RNA), a molecule essential for various biological processes. These approaches have gained significant attention, particularly in the fields of medicine and biotechnology.
RNA therapeutics involve using RNA molecules to treat or prevent diseases by modulating gene expression or protein production.
Types:
mRNA (messenger RNA) Therapeutics introduce synthetic mRNA into cells to instruct them to produce specific proteins. This approach has shown promise in treating genetic disorders, cancers, and other diseases.
siRNA (small interfering RNA) Therapeutics: Use short RNA molecules to interfere with the expression of specific genes, blocking the production of harmful proteins. This approach is being explored for conditions such as viral infections and certain genetic disorders.
Antisense Oligonucleotide Therapeutics: Utilize short RNA or DNA molecules to bind to target mRNA, modulating the translation of genetic information into proteins. This approach is being studied for various diseases, including neurodegenerative disorders.
RNA vaccines are a type of vaccine that uses RNA molecules to stimulate an immune response against specific pathogens, such as viruses. RNA-based therapeutics and vaccines can be developed relatively quickly compared to traditional methods. This is particularly evident in the rapid development of COVID-19 mRNA vaccines. RNA therapies can be designed with high precision to target specific genes or proteins, offering a more targeted therapeutic approach. The modular nature of RNA allows for easy adaptation to address different diseases by altering the sequence of the RNA.
RNA therapies hold promise for personalized medicine by targeting specific genetic mutations associated with individual patients' conditions. While RNA therapeutics and vaccines show great promise, ongoing research is exploring their safety, efficacy, and potential applications for a wide range of diseases beyond those addressed by current vaccines.
Key Features:
The report on RNA Therapeutics and Vaccines market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the RNA Therapeutics and Vaccines market. It may include historical data, market segmentation by Type (e.g., mRNA (messenger RNA) Therapeutics, siRNA (small interfering RNA) Therapeutics), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the RNA Therapeutics and Vaccines market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the RNA Therapeutics and Vaccines market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the RNA Therapeutics and Vaccines industry. This include advancements in RNA Therapeutics and Vaccines technology, RNA Therapeutics and Vaccines new entrants, RNA Therapeutics and Vaccines new investment, and other innovations that are shaping the future of RNA Therapeutics and Vaccines.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the RNA Therapeutics and Vaccines market. It includes factors influencing customer ' purchasing decisions, preferences for RNA Therapeutics and Vaccines product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the RNA Therapeutics and Vaccines market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting RNA Therapeutics and Vaccines market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the RNA Therapeutics and Vaccines market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the RNA Therapeutics and Vaccines industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the RNA Therapeutics and Vaccines market.
Market Segmentation:
RNA Therapeutics and Vaccines market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Segmentation by type
What is the 10-year outlook for the global RNA Therapeutics and Vaccines market?
What factors are driving RNA Therapeutics and Vaccines market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do RNA Therapeutics and Vaccines market opportunities vary by end market size?
How does RNA Therapeutics and Vaccines break out type, application?
According to our LPI (LP Information) latest study, the global RNA Therapeutics and Vaccines market size was valued at US$ million in 2022. With growing demand in downstream market, the RNA Therapeutics and Vaccines is forecast to a readjusted size of US$ million by 2029 with a CAGR of % during review period.
The research report highlights the growth potential of the global RNA Therapeutics and Vaccines market. RNA Therapeutics and Vaccines are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of RNA Therapeutics and Vaccines. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the RNA Therapeutics and Vaccines market.
RNA therapeutics and vaccines represent a groundbreaking approach to medical interventions that leverage the unique properties of ribonucleic acid (RNA), a molecule essential for various biological processes. These approaches have gained significant attention, particularly in the fields of medicine and biotechnology.
RNA therapeutics involve using RNA molecules to treat or prevent diseases by modulating gene expression or protein production.
Types:
mRNA (messenger RNA) Therapeutics introduce synthetic mRNA into cells to instruct them to produce specific proteins. This approach has shown promise in treating genetic disorders, cancers, and other diseases.
siRNA (small interfering RNA) Therapeutics: Use short RNA molecules to interfere with the expression of specific genes, blocking the production of harmful proteins. This approach is being explored for conditions such as viral infections and certain genetic disorders.
Antisense Oligonucleotide Therapeutics: Utilize short RNA or DNA molecules to bind to target mRNA, modulating the translation of genetic information into proteins. This approach is being studied for various diseases, including neurodegenerative disorders.
RNA vaccines are a type of vaccine that uses RNA molecules to stimulate an immune response against specific pathogens, such as viruses. RNA-based therapeutics and vaccines can be developed relatively quickly compared to traditional methods. This is particularly evident in the rapid development of COVID-19 mRNA vaccines. RNA therapies can be designed with high precision to target specific genes or proteins, offering a more targeted therapeutic approach. The modular nature of RNA allows for easy adaptation to address different diseases by altering the sequence of the RNA.
RNA therapies hold promise for personalized medicine by targeting specific genetic mutations associated with individual patients' conditions. While RNA therapeutics and vaccines show great promise, ongoing research is exploring their safety, efficacy, and potential applications for a wide range of diseases beyond those addressed by current vaccines.
Key Features:
The report on RNA Therapeutics and Vaccines market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the RNA Therapeutics and Vaccines market. It may include historical data, market segmentation by Type (e.g., mRNA (messenger RNA) Therapeutics, siRNA (small interfering RNA) Therapeutics), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the RNA Therapeutics and Vaccines market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the RNA Therapeutics and Vaccines market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the RNA Therapeutics and Vaccines industry. This include advancements in RNA Therapeutics and Vaccines technology, RNA Therapeutics and Vaccines new entrants, RNA Therapeutics and Vaccines new investment, and other innovations that are shaping the future of RNA Therapeutics and Vaccines.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the RNA Therapeutics and Vaccines market. It includes factors influencing customer ' purchasing decisions, preferences for RNA Therapeutics and Vaccines product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the RNA Therapeutics and Vaccines market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting RNA Therapeutics and Vaccines market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the RNA Therapeutics and Vaccines market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the RNA Therapeutics and Vaccines industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the RNA Therapeutics and Vaccines market.
Market Segmentation:
RNA Therapeutics and Vaccines market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Segmentation by type
- mRNA (messenger RNA) Therapeutics
- siRNA (small interfering RNA) Therapeutics
- Antisense Oligonucleotide Therapeutics
- Hospitals
- Research Institutions
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Moderna
- BioNTech (Pfizer)
- Sanofi
- Novartis
- CureVac
- CSL
- Arrowhead Pharmaceuticals
- Alnylam Pharmaceuticals
- GlaxoSmithKline (GSK)
- Ionis Pharmaceuticals
- Regulus Therapeutics
- Roche
- AstraZeneca
- Sarepta Therapeutics
- Orna Therapeutics
What is the 10-year outlook for the global RNA Therapeutics and Vaccines market?
What factors are driving RNA Therapeutics and Vaccines market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do RNA Therapeutics and Vaccines market opportunities vary by end market size?
How does RNA Therapeutics and Vaccines break out type, application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global RNA Therapeutics and Vaccines Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for RNA Therapeutics and Vaccines by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for RNA Therapeutics and Vaccines by Country/Region, 2018, 2022 & 2029
2.2 RNA Therapeutics and Vaccines Segment by Type
2.2.1 mRNA (messenger RNA) Therapeutics
2.2.2 siRNA (small interfering RNA) Therapeutics
2.2.3 Antisense Oligonucleotide Therapeutics
2.3 RNA Therapeutics and Vaccines Sales by Type
2.3.1 Global RNA Therapeutics and Vaccines Sales Market Share by Type (2018-2023)
2.3.2 Global RNA Therapeutics and Vaccines Revenue and Market Share by Type (2018-2023)
2.3.3 Global RNA Therapeutics and Vaccines Sale Price by Type (2018-2023)
2.4 RNA Therapeutics and Vaccines Segment by Application
2.4.1 Hospitals
2.4.2 Research Institutions
2.5 RNA Therapeutics and Vaccines Sales by Application
2.5.1 Global RNA Therapeutics and Vaccines Sale Market Share by Application (2018-2023)
2.5.2 Global RNA Therapeutics and Vaccines Revenue and Market Share by Application (2018-2023)
2.5.3 Global RNA Therapeutics and Vaccines Sale Price by Application (2018-2023)
3 GLOBAL RNA THERAPEUTICS AND VACCINES BY COMPANY
3.1 Global RNA Therapeutics and Vaccines Breakdown Data by Company
3.1.1 Global RNA Therapeutics and Vaccines Annual Sales by Company (2018-2023)
3.1.2 Global RNA Therapeutics and Vaccines Sales Market Share by Company (2018-2023)
3.2 Global RNA Therapeutics and Vaccines Annual Revenue by Company (2018-2023)
3.2.1 Global RNA Therapeutics and Vaccines Revenue by Company (2018-2023)
3.2.2 Global RNA Therapeutics and Vaccines Revenue Market Share by Company (2018-2023)
3.3 Global RNA Therapeutics and Vaccines Sale Price by Company
3.4 Key Manufacturers RNA Therapeutics and Vaccines Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers RNA Therapeutics and Vaccines Product Location Distribution
3.4.2 Players RNA Therapeutics and Vaccines Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR RNA THERAPEUTICS AND VACCINES BY GEOGRAPHIC REGION
4.1 World Historic RNA Therapeutics and Vaccines Market Size by Geographic Region (2018-2023)
4.1.1 Global RNA Therapeutics and Vaccines Annual Sales by Geographic Region (2018-2023)
4.1.2 Global RNA Therapeutics and Vaccines Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic RNA Therapeutics and Vaccines Market Size by Country/Region (2018-2023)
4.2.1 Global RNA Therapeutics and Vaccines Annual Sales by Country/Region (2018-2023)
4.2.2 Global RNA Therapeutics and Vaccines Annual Revenue by Country/Region (2018-2023)
4.3 Americas RNA Therapeutics and Vaccines Sales Growth
4.4 APAC RNA Therapeutics and Vaccines Sales Growth
4.5 Europe RNA Therapeutics and Vaccines Sales Growth
4.6 Middle East & Africa RNA Therapeutics and Vaccines Sales Growth
5 AMERICAS
5.1 Americas RNA Therapeutics and Vaccines Sales by Country
5.1.1 Americas RNA Therapeutics and Vaccines Sales by Country (2018-2023)
5.1.2 Americas RNA Therapeutics and Vaccines Revenue by Country (2018-2023)
5.2 Americas RNA Therapeutics and Vaccines Sales by Type
5.3 Americas RNA Therapeutics and Vaccines Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC RNA Therapeutics and Vaccines Sales by Region
6.1.1 APAC RNA Therapeutics and Vaccines Sales by Region (2018-2023)
6.1.2 APAC RNA Therapeutics and Vaccines Revenue by Region (2018-2023)
6.2 APAC RNA Therapeutics and Vaccines Sales by Type
6.3 APAC RNA Therapeutics and Vaccines Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe RNA Therapeutics and Vaccines by Country
7.1.1 Europe RNA Therapeutics and Vaccines Sales by Country (2018-2023)
7.1.2 Europe RNA Therapeutics and Vaccines Revenue by Country (2018-2023)
7.2 Europe RNA Therapeutics and Vaccines Sales by Type
7.3 Europe RNA Therapeutics and Vaccines Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa RNA Therapeutics and Vaccines by Country
8.1.1 Middle East & Africa RNA Therapeutics and Vaccines Sales by Country (2018-2023)
8.1.2 Middle East & Africa RNA Therapeutics and Vaccines Revenue by Country (2018-2023)
8.2 Middle East & Africa RNA Therapeutics and Vaccines Sales by Type
8.3 Middle East & Africa RNA Therapeutics and Vaccines Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of RNA Therapeutics and Vaccines
10.3 Manufacturing Process Analysis of RNA Therapeutics and Vaccines
10.4 Industry Chain Structure of RNA Therapeutics and Vaccines
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 RNA Therapeutics and Vaccines Distributors
11.3 RNA Therapeutics and Vaccines Customer
12 WORLD FORECAST REVIEW FOR RNA THERAPEUTICS AND VACCINES BY GEOGRAPHIC REGION
12.1 Global RNA Therapeutics and Vaccines Market Size Forecast by Region
12.1.1 Global RNA Therapeutics and Vaccines Forecast by Region (2024-2029)
12.1.2 Global RNA Therapeutics and Vaccines Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global RNA Therapeutics and Vaccines Forecast by Type
12.7 Global RNA Therapeutics and Vaccines Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Moderna
13.1.1 Moderna Company Information
13.1.2 Moderna RNA Therapeutics and Vaccines Product Portfolios and Specifications
13.1.3 Moderna RNA Therapeutics and Vaccines Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Moderna Main Business Overview
13.1.5 Moderna Latest Developments
13.2 BioNTech (Pfizer)
13.2.1 BioNTech (Pfizer) Company Information
13.2.2 BioNTech (Pfizer) RNA Therapeutics and Vaccines Product Portfolios and Specifications
13.2.3 BioNTech (Pfizer) RNA Therapeutics and Vaccines Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 BioNTech (Pfizer) Main Business Overview
13.2.5 BioNTech (Pfizer) Latest Developments
13.3 Sanofi
13.3.1 Sanofi Company Information
13.3.2 Sanofi RNA Therapeutics and Vaccines Product Portfolios and Specifications
13.3.3 Sanofi RNA Therapeutics and Vaccines Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Sanofi Main Business Overview
13.3.5 Sanofi Latest Developments
13.4 Novartis
13.4.1 Novartis Company Information
13.4.2 Novartis RNA Therapeutics and Vaccines Product Portfolios and Specifications
13.4.3 Novartis RNA Therapeutics and Vaccines Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Novartis Main Business Overview
13.4.5 Novartis Latest Developments
13.5 CureVac
13.5.1 CureVac Company Information
13.5.2 CureVac RNA Therapeutics and Vaccines Product Portfolios and Specifications
13.5.3 CureVac RNA Therapeutics and Vaccines Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 CureVac Main Business Overview
13.5.5 CureVac Latest Developments
13.6 CSL
13.6.1 CSL Company Information
13.6.2 CSL RNA Therapeutics and Vaccines Product Portfolios and Specifications
13.6.3 CSL RNA Therapeutics and Vaccines Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 CSL Main Business Overview
13.6.5 CSL Latest Developments
13.7 Arrowhead Pharmaceuticals
13.7.1 Arrowhead Pharmaceuticals Company Information
13.7.2 Arrowhead Pharmaceuticals RNA Therapeutics and Vaccines Product Portfolios and Specifications
13.7.3 Arrowhead Pharmaceuticals RNA Therapeutics and Vaccines Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Arrowhead Pharmaceuticals Main Business Overview
13.7.5 Arrowhead Pharmaceuticals Latest Developments
13.8 Alnylam Pharmaceuticals
13.8.1 Alnylam Pharmaceuticals Company Information
13.8.2 Alnylam Pharmaceuticals RNA Therapeutics and Vaccines Product Portfolios and Specifications
13.8.3 Alnylam Pharmaceuticals RNA Therapeutics and Vaccines Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Alnylam Pharmaceuticals Main Business Overview
13.8.5 Alnylam Pharmaceuticals Latest Developments
13.9 GlaxoSmithKline (GSK)
13.9.1 GlaxoSmithKline (GSK) Company Information
13.9.2 GlaxoSmithKline (GSK) RNA Therapeutics and Vaccines Product Portfolios and Specifications
13.9.3 GlaxoSmithKline (GSK) RNA Therapeutics and Vaccines Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 GlaxoSmithKline (GSK) Main Business Overview
13.9.5 GlaxoSmithKline (GSK) Latest Developments
13.10 Ionis Pharmaceuticals
13.10.1 Ionis Pharmaceuticals Company Information
13.10.2 Ionis Pharmaceuticals RNA Therapeutics and Vaccines Product Portfolios and Specifications
13.10.3 Ionis Pharmaceuticals RNA Therapeutics and Vaccines Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Ionis Pharmaceuticals Main Business Overview
13.10.5 Ionis Pharmaceuticals Latest Developments
13.11 Regulus Therapeutics
13.11.1 Regulus Therapeutics Company Information
13.11.2 Regulus Therapeutics RNA Therapeutics and Vaccines Product Portfolios and Specifications
13.11.3 Regulus Therapeutics RNA Therapeutics and Vaccines Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 Regulus Therapeutics Main Business Overview
13.11.5 Regulus Therapeutics Latest Developments
13.12 Roche
13.12.1 Roche Company Information
13.12.2 Roche RNA Therapeutics and Vaccines Product Portfolios and Specifications
13.12.3 Roche RNA Therapeutics and Vaccines Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 Roche Main Business Overview
13.12.5 Roche Latest Developments
13.13 AstraZeneca
13.13.1 AstraZeneca Company Information
13.13.2 AstraZeneca RNA Therapeutics and Vaccines Product Portfolios and Specifications
13.13.3 AstraZeneca RNA Therapeutics and Vaccines Sales, Revenue, Price and Gross Margin (2018-2023)
13.13.4 AstraZeneca Main Business Overview
13.13.5 AstraZeneca Latest Developments
13.14 Sarepta Therapeutics
13.14.1 Sarepta Therapeutics Company Information
13.14.2 Sarepta Therapeutics RNA Therapeutics and Vaccines Product Portfolios and Specifications
13.14.3 Sarepta Therapeutics RNA Therapeutics and Vaccines Sales, Revenue, Price and Gross Margin (2018-2023)
13.14.4 Sarepta Therapeutics Main Business Overview
13.14.5 Sarepta Therapeutics Latest Developments
13.15 Orna Therapeutics
13.15.1 Orna Therapeutics Company Information
13.15.2 Orna Therapeutics RNA Therapeutics and Vaccines Product Portfolios and Specifications
13.15.3 Orna Therapeutics RNA Therapeutics and Vaccines Sales, Revenue, Price and Gross Margin (2018-2023)
13.15.4 Orna Therapeutics Main Business Overview
13.15.5 Orna Therapeutics Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global RNA Therapeutics and Vaccines Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for RNA Therapeutics and Vaccines by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for RNA Therapeutics and Vaccines by Country/Region, 2018, 2022 & 2029
2.2 RNA Therapeutics and Vaccines Segment by Type
2.2.1 mRNA (messenger RNA) Therapeutics
2.2.2 siRNA (small interfering RNA) Therapeutics
2.2.3 Antisense Oligonucleotide Therapeutics
2.3 RNA Therapeutics and Vaccines Sales by Type
2.3.1 Global RNA Therapeutics and Vaccines Sales Market Share by Type (2018-2023)
2.3.2 Global RNA Therapeutics and Vaccines Revenue and Market Share by Type (2018-2023)
2.3.3 Global RNA Therapeutics and Vaccines Sale Price by Type (2018-2023)
2.4 RNA Therapeutics and Vaccines Segment by Application
2.4.1 Hospitals
2.4.2 Research Institutions
2.5 RNA Therapeutics and Vaccines Sales by Application
2.5.1 Global RNA Therapeutics and Vaccines Sale Market Share by Application (2018-2023)
2.5.2 Global RNA Therapeutics and Vaccines Revenue and Market Share by Application (2018-2023)
2.5.3 Global RNA Therapeutics and Vaccines Sale Price by Application (2018-2023)
3 GLOBAL RNA THERAPEUTICS AND VACCINES BY COMPANY
3.1 Global RNA Therapeutics and Vaccines Breakdown Data by Company
3.1.1 Global RNA Therapeutics and Vaccines Annual Sales by Company (2018-2023)
3.1.2 Global RNA Therapeutics and Vaccines Sales Market Share by Company (2018-2023)
3.2 Global RNA Therapeutics and Vaccines Annual Revenue by Company (2018-2023)
3.2.1 Global RNA Therapeutics and Vaccines Revenue by Company (2018-2023)
3.2.2 Global RNA Therapeutics and Vaccines Revenue Market Share by Company (2018-2023)
3.3 Global RNA Therapeutics and Vaccines Sale Price by Company
3.4 Key Manufacturers RNA Therapeutics and Vaccines Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers RNA Therapeutics and Vaccines Product Location Distribution
3.4.2 Players RNA Therapeutics and Vaccines Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR RNA THERAPEUTICS AND VACCINES BY GEOGRAPHIC REGION
4.1 World Historic RNA Therapeutics and Vaccines Market Size by Geographic Region (2018-2023)
4.1.1 Global RNA Therapeutics and Vaccines Annual Sales by Geographic Region (2018-2023)
4.1.2 Global RNA Therapeutics and Vaccines Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic RNA Therapeutics and Vaccines Market Size by Country/Region (2018-2023)
4.2.1 Global RNA Therapeutics and Vaccines Annual Sales by Country/Region (2018-2023)
4.2.2 Global RNA Therapeutics and Vaccines Annual Revenue by Country/Region (2018-2023)
4.3 Americas RNA Therapeutics and Vaccines Sales Growth
4.4 APAC RNA Therapeutics and Vaccines Sales Growth
4.5 Europe RNA Therapeutics and Vaccines Sales Growth
4.6 Middle East & Africa RNA Therapeutics and Vaccines Sales Growth
5 AMERICAS
5.1 Americas RNA Therapeutics and Vaccines Sales by Country
5.1.1 Americas RNA Therapeutics and Vaccines Sales by Country (2018-2023)
5.1.2 Americas RNA Therapeutics and Vaccines Revenue by Country (2018-2023)
5.2 Americas RNA Therapeutics and Vaccines Sales by Type
5.3 Americas RNA Therapeutics and Vaccines Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC RNA Therapeutics and Vaccines Sales by Region
6.1.1 APAC RNA Therapeutics and Vaccines Sales by Region (2018-2023)
6.1.2 APAC RNA Therapeutics and Vaccines Revenue by Region (2018-2023)
6.2 APAC RNA Therapeutics and Vaccines Sales by Type
6.3 APAC RNA Therapeutics and Vaccines Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe RNA Therapeutics and Vaccines by Country
7.1.1 Europe RNA Therapeutics and Vaccines Sales by Country (2018-2023)
7.1.2 Europe RNA Therapeutics and Vaccines Revenue by Country (2018-2023)
7.2 Europe RNA Therapeutics and Vaccines Sales by Type
7.3 Europe RNA Therapeutics and Vaccines Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa RNA Therapeutics and Vaccines by Country
8.1.1 Middle East & Africa RNA Therapeutics and Vaccines Sales by Country (2018-2023)
8.1.2 Middle East & Africa RNA Therapeutics and Vaccines Revenue by Country (2018-2023)
8.2 Middle East & Africa RNA Therapeutics and Vaccines Sales by Type
8.3 Middle East & Africa RNA Therapeutics and Vaccines Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of RNA Therapeutics and Vaccines
10.3 Manufacturing Process Analysis of RNA Therapeutics and Vaccines
10.4 Industry Chain Structure of RNA Therapeutics and Vaccines
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 RNA Therapeutics and Vaccines Distributors
11.3 RNA Therapeutics and Vaccines Customer
12 WORLD FORECAST REVIEW FOR RNA THERAPEUTICS AND VACCINES BY GEOGRAPHIC REGION
12.1 Global RNA Therapeutics and Vaccines Market Size Forecast by Region
12.1.1 Global RNA Therapeutics and Vaccines Forecast by Region (2024-2029)
12.1.2 Global RNA Therapeutics and Vaccines Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global RNA Therapeutics and Vaccines Forecast by Type
12.7 Global RNA Therapeutics and Vaccines Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Moderna
13.1.1 Moderna Company Information
13.1.2 Moderna RNA Therapeutics and Vaccines Product Portfolios and Specifications
13.1.3 Moderna RNA Therapeutics and Vaccines Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Moderna Main Business Overview
13.1.5 Moderna Latest Developments
13.2 BioNTech (Pfizer)
13.2.1 BioNTech (Pfizer) Company Information
13.2.2 BioNTech (Pfizer) RNA Therapeutics and Vaccines Product Portfolios and Specifications
13.2.3 BioNTech (Pfizer) RNA Therapeutics and Vaccines Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 BioNTech (Pfizer) Main Business Overview
13.2.5 BioNTech (Pfizer) Latest Developments
13.3 Sanofi
13.3.1 Sanofi Company Information
13.3.2 Sanofi RNA Therapeutics and Vaccines Product Portfolios and Specifications
13.3.3 Sanofi RNA Therapeutics and Vaccines Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Sanofi Main Business Overview
13.3.5 Sanofi Latest Developments
13.4 Novartis
13.4.1 Novartis Company Information
13.4.2 Novartis RNA Therapeutics and Vaccines Product Portfolios and Specifications
13.4.3 Novartis RNA Therapeutics and Vaccines Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Novartis Main Business Overview
13.4.5 Novartis Latest Developments
13.5 CureVac
13.5.1 CureVac Company Information
13.5.2 CureVac RNA Therapeutics and Vaccines Product Portfolios and Specifications
13.5.3 CureVac RNA Therapeutics and Vaccines Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 CureVac Main Business Overview
13.5.5 CureVac Latest Developments
13.6 CSL
13.6.1 CSL Company Information
13.6.2 CSL RNA Therapeutics and Vaccines Product Portfolios and Specifications
13.6.3 CSL RNA Therapeutics and Vaccines Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 CSL Main Business Overview
13.6.5 CSL Latest Developments
13.7 Arrowhead Pharmaceuticals
13.7.1 Arrowhead Pharmaceuticals Company Information
13.7.2 Arrowhead Pharmaceuticals RNA Therapeutics and Vaccines Product Portfolios and Specifications
13.7.3 Arrowhead Pharmaceuticals RNA Therapeutics and Vaccines Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Arrowhead Pharmaceuticals Main Business Overview
13.7.5 Arrowhead Pharmaceuticals Latest Developments
13.8 Alnylam Pharmaceuticals
13.8.1 Alnylam Pharmaceuticals Company Information
13.8.2 Alnylam Pharmaceuticals RNA Therapeutics and Vaccines Product Portfolios and Specifications
13.8.3 Alnylam Pharmaceuticals RNA Therapeutics and Vaccines Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Alnylam Pharmaceuticals Main Business Overview
13.8.5 Alnylam Pharmaceuticals Latest Developments
13.9 GlaxoSmithKline (GSK)
13.9.1 GlaxoSmithKline (GSK) Company Information
13.9.2 GlaxoSmithKline (GSK) RNA Therapeutics and Vaccines Product Portfolios and Specifications
13.9.3 GlaxoSmithKline (GSK) RNA Therapeutics and Vaccines Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 GlaxoSmithKline (GSK) Main Business Overview
13.9.5 GlaxoSmithKline (GSK) Latest Developments
13.10 Ionis Pharmaceuticals
13.10.1 Ionis Pharmaceuticals Company Information
13.10.2 Ionis Pharmaceuticals RNA Therapeutics and Vaccines Product Portfolios and Specifications
13.10.3 Ionis Pharmaceuticals RNA Therapeutics and Vaccines Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Ionis Pharmaceuticals Main Business Overview
13.10.5 Ionis Pharmaceuticals Latest Developments
13.11 Regulus Therapeutics
13.11.1 Regulus Therapeutics Company Information
13.11.2 Regulus Therapeutics RNA Therapeutics and Vaccines Product Portfolios and Specifications
13.11.3 Regulus Therapeutics RNA Therapeutics and Vaccines Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 Regulus Therapeutics Main Business Overview
13.11.5 Regulus Therapeutics Latest Developments
13.12 Roche
13.12.1 Roche Company Information
13.12.2 Roche RNA Therapeutics and Vaccines Product Portfolios and Specifications
13.12.3 Roche RNA Therapeutics and Vaccines Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 Roche Main Business Overview
13.12.5 Roche Latest Developments
13.13 AstraZeneca
13.13.1 AstraZeneca Company Information
13.13.2 AstraZeneca RNA Therapeutics and Vaccines Product Portfolios and Specifications
13.13.3 AstraZeneca RNA Therapeutics and Vaccines Sales, Revenue, Price and Gross Margin (2018-2023)
13.13.4 AstraZeneca Main Business Overview
13.13.5 AstraZeneca Latest Developments
13.14 Sarepta Therapeutics
13.14.1 Sarepta Therapeutics Company Information
13.14.2 Sarepta Therapeutics RNA Therapeutics and Vaccines Product Portfolios and Specifications
13.14.3 Sarepta Therapeutics RNA Therapeutics and Vaccines Sales, Revenue, Price and Gross Margin (2018-2023)
13.14.4 Sarepta Therapeutics Main Business Overview
13.14.5 Sarepta Therapeutics Latest Developments
13.15 Orna Therapeutics
13.15.1 Orna Therapeutics Company Information
13.15.2 Orna Therapeutics RNA Therapeutics and Vaccines Product Portfolios and Specifications
13.15.3 Orna Therapeutics RNA Therapeutics and Vaccines Sales, Revenue, Price and Gross Margin (2018-2023)
13.15.4 Orna Therapeutics Main Business Overview
13.15.5 Orna Therapeutics Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. RNA Therapeutics and Vaccines Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. RNA Therapeutics and Vaccines Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of mRNA (messenger RNA) Therapeutics
Table 4. Major Players of siRNA (small interfering RNA) Therapeutics
Table 5. Major Players of Antisense Oligonucleotide Therapeutics
Table 6. Global RNA Therapeutics and Vaccines Sales by Type (2018-2023) & (K Units)
Table 7. Global RNA Therapeutics and Vaccines Sales Market Share by Type (2018-2023)
Table 8. Global RNA Therapeutics and Vaccines Revenue by Type (2018-2023) & ($ million)
Table 9. Global RNA Therapeutics and Vaccines Revenue Market Share by Type (2018-2023)
Table 10. Global RNA Therapeutics and Vaccines Sale Price by Type (2018-2023) & (US$/Unit)
Table 11. Global RNA Therapeutics and Vaccines Sales by Application (2018-2023) & (K Units)
Table 12. Global RNA Therapeutics and Vaccines Sales Market Share by Application (2018-2023)
Table 13. Global RNA Therapeutics and Vaccines Revenue by Application (2018-2023)
Table 14. Global RNA Therapeutics and Vaccines Revenue Market Share by Application (2018-2023)
Table 15. Global RNA Therapeutics and Vaccines Sale Price by Application (2018-2023) & (US$/Unit)
Table 16. Global RNA Therapeutics and Vaccines Sales by Company (2018-2023) & (K Units)
Table 17. Global RNA Therapeutics and Vaccines Sales Market Share by Company (2018-2023)
Table 18. Global RNA Therapeutics and Vaccines Revenue by Company (2018-2023) ($ Millions)
Table 19. Global RNA Therapeutics and Vaccines Revenue Market Share by Company (2018-2023)
Table 20. Global RNA Therapeutics and Vaccines Sale Price by Company (2018-2023) & (US$/Unit)
Table 21. Key Manufacturers RNA Therapeutics and Vaccines Producing Area Distribution and Sales Area
Table 22. Players RNA Therapeutics and Vaccines Products Offered
Table 23. RNA Therapeutics and Vaccines Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 24. New Products and Potential Entrants
Table 25. Mergers & Acquisitions, Expansion
Table 26. Global RNA Therapeutics and Vaccines Sales by Geographic Region (2018-2023) & (K Units)
Table 27. Global RNA Therapeutics and Vaccines Sales Market Share Geographic Region (2018-2023)
Table 28. Global RNA Therapeutics and Vaccines Revenue by Geographic Region (2018-2023) & ($ millions)
Table 29. Global RNA Therapeutics and Vaccines Revenue Market Share by Geographic Region (2018-2023)
Table 30. Global RNA Therapeutics and Vaccines Sales by Country/Region (2018-2023) & (K Units)
Table 31. Global RNA Therapeutics and Vaccines Sales Market Share by Country/Region (2018-2023)
Table 32. Global RNA Therapeutics and Vaccines Revenue by Country/Region (2018-2023) & ($ millions)
Table 33. Global RNA Therapeutics and Vaccines Revenue Market Share by Country/Region (2018-2023)
Table 34. Americas RNA Therapeutics and Vaccines Sales by Country (2018-2023) & (K Units)
Table 35. Americas RNA Therapeutics and Vaccines Sales Market Share by Country (2018-2023)
Table 36. Americas RNA Therapeutics and Vaccines Revenue by Country (2018-2023) & ($ Millions)
Table 37. Americas RNA Therapeutics and Vaccines Revenue Market Share by Country (2018-2023)
Table 38. Americas RNA Therapeutics and Vaccines Sales by Type (2018-2023) & (K Units)
Table 39. Americas RNA Therapeutics and Vaccines Sales by Application (2018-2023) & (K Units)
Table 40. APAC RNA Therapeutics and Vaccines Sales by Region (2018-2023) & (K Units)
Table 41. APAC RNA Therapeutics and Vaccines Sales Market Share by Region (2018-2023)
Table 42. APAC RNA Therapeutics and Vaccines Revenue by Region (2018-2023) & ($ Millions)
Table 43. APAC RNA Therapeutics and Vaccines Revenue Market Share by Region (2018-2023)
Table 44. APAC RNA Therapeutics and Vaccines Sales by Type (2018-2023) & (K Units)
Table 45. APAC RNA Therapeutics and Vaccines Sales by Application (2018-2023) & (K Units)
Table 46. Europe RNA Therapeutics and Vaccines Sales by Country (2018-2023) & (K Units)
Table 47. Europe RNA Therapeutics and Vaccines Sales Market Share by Country (2018-2023)
Table 48. Europe RNA Therapeutics and Vaccines Revenue by Country (2018-2023) & ($ Millions)
Table 49. Europe RNA Therapeutics and Vaccines Revenue Market Share by Country (2018-2023)
Table 50. Europe RNA Therapeutics and Vaccines Sales by Type (2018-2023) & (K Units)
Table 51. Europe RNA Therapeutics and Vaccines Sales by Application (2018-2023) & (K Units)
Table 52. Middle East & Africa RNA Therapeutics and Vaccines Sales by Country (2018-2023) & (K Units)
Table 53. Middle East & Africa RNA Therapeutics and Vaccines Sales Market Share by Country (2018-2023)
Table 54. Middle East & Africa RNA Therapeutics and Vaccines Revenue by Country (2018-2023) & ($ Millions)
Table 55. Middle East & Africa RNA Therapeutics and Vaccines Revenue Market Share by Country (2018-2023)
Table 56. Middle East & Africa RNA Therapeutics and Vaccines Sales by Type (2018-2023) & (K Units)
Table 57. Middle East & Africa RNA Therapeutics and Vaccines Sales by Application (2018-2023) & (K Units)
Table 58. Key Market Drivers & Growth Opportunities of RNA Therapeutics and Vaccines
Table 59. Key Market Challenges & Risks of RNA Therapeutics and Vaccines
Table 60. Key Industry Trends of RNA Therapeutics and Vaccines
Table 61. RNA Therapeutics and Vaccines Raw Material
Table 62. Key Suppliers of Raw Materials
Table 63. RNA Therapeutics and Vaccines Distributors List
Table 64. RNA Therapeutics and Vaccines Customer List
Table 65. Global RNA Therapeutics and Vaccines Sales Forecast by Region (2024-2029) & (K Units)
Table 66. Global RNA Therapeutics and Vaccines Revenue Forecast by Region (2024-2029) & ($ millions)
Table 67. Americas RNA Therapeutics and Vaccines Sales Forecast by Country (2024-2029) & (K Units)
Table 68. Americas RNA Therapeutics and Vaccines Revenue Forecast by Country (2024-2029) & ($ millions)
Table 69. APAC RNA Therapeutics and Vaccines Sales Forecast by Region (2024-2029) & (K Units)
Table 70. APAC RNA Therapeutics and Vaccines Revenue Forecast by Region (2024-2029) & ($ millions)
Table 71. Europe RNA Therapeutics and Vaccines Sales Forecast by Country (2024-2029) & (K Units)
Table 72. Europe RNA Therapeutics and Vaccines Revenue Forecast by Country (2024-2029) & ($ millions)
Table 73. Middle East & Africa RNA Therapeutics and Vaccines Sales Forecast by Country (2024-2029) & (K Units)
Table 74. Middle East & Africa RNA Therapeutics and Vaccines Revenue Forecast by Country (2024-2029) & ($ millions)
Table 75. Global RNA Therapeutics and Vaccines Sales Forecast by Type (2024-2029) & (K Units)
Table 76. Global RNA Therapeutics and Vaccines Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 77. Global RNA Therapeutics and Vaccines Sales Forecast by Application (2024-2029) & (K Units)
Table 78. Global RNA Therapeutics and Vaccines Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 79. Moderna Basic Information, RNA Therapeutics and Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 80. Moderna RNA Therapeutics and Vaccines Product Portfolios and Specifications
Table 81. Moderna RNA Therapeutics and Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 82. Moderna Main Business
Table 83. Moderna Latest Developments
Table 84. BioNTech (Pfizer) Basic Information, RNA Therapeutics and Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 85. BioNTech (Pfizer) RNA Therapeutics and Vaccines Product Portfolios and Specifications
Table 86. BioNTech (Pfizer) RNA Therapeutics and Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 87. BioNTech (Pfizer) Main Business
Table 88. BioNTech (Pfizer) Latest Developments
Table 89. Sanofi Basic Information, RNA Therapeutics and Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 90. Sanofi RNA Therapeutics and Vaccines Product Portfolios and Specifications
Table 91. Sanofi RNA Therapeutics and Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 92. Sanofi Main Business
Table 93. Sanofi Latest Developments
Table 94. Novartis Basic Information, RNA Therapeutics and Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 95. Novartis RNA Therapeutics and Vaccines Product Portfolios and Specifications
Table 96. Novartis RNA Therapeutics and Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 97. Novartis Main Business
Table 98. Novartis Latest Developments
Table 99. CureVac Basic Information, RNA Therapeutics and Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 100. CureVac RNA Therapeutics and Vaccines Product Portfolios and Specifications
Table 101. CureVac RNA Therapeutics and Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 102. CureVac Main Business
Table 103. CureVac Latest Developments
Table 104. CSL Basic Information, RNA Therapeutics and Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 105. CSL RNA Therapeutics and Vaccines Product Portfolios and Specifications
Table 106. CSL RNA Therapeutics and Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 107. CSL Main Business
Table 108. CSL Latest Developments
Table 109. Arrowhead Pharmaceuticals Basic Information, RNA Therapeutics and Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 110. Arrowhead Pharmaceuticals RNA Therapeutics and Vaccines Product Portfolios and Specifications
Table 111. Arrowhead Pharmaceuticals RNA Therapeutics and Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 112. Arrowhead Pharmaceuticals Main Business
Table 113. Arrowhead Pharmaceuticals Latest Developments
Table 114. Alnylam Pharmaceuticals Basic Information, RNA Therapeutics and Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 115. Alnylam Pharmaceuticals RNA Therapeutics and Vaccines Product Portfolios and Specifications
Table 116. Alnylam Pharmaceuticals RNA Therapeutics and Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 117. Alnylam Pharmaceuticals Main Business
Table 118. Alnylam Pharmaceuticals Latest Developments
Table 119. GlaxoSmithKline (GSK) Basic Information, RNA Therapeutics and Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 120. GlaxoSmithKline (GSK) RNA Therapeutics and Vaccines Product Portfolios and Specifications
Table 121. GlaxoSmithKline (GSK) RNA Therapeutics and Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 122. GlaxoSmithKline (GSK) Main Business
Table 123. GlaxoSmithKline (GSK) Latest Developments
Table 124. Ionis Pharmaceuticals Basic Information, RNA Therapeutics and Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 125. Ionis Pharmaceuticals RNA Therapeutics and Vaccines Product Portfolios and Specifications
Table 126. Ionis Pharmaceuticals RNA Therapeutics and Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 127. Ionis Pharmaceuticals Main Business
Table 128. Ionis Pharmaceuticals Latest Developments
Table 129. Regulus Therapeutics Basic Information, RNA Therapeutics and Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 130. Regulus Therapeutics RNA Therapeutics and Vaccines Product Portfolios and Specifications
Table 131. Regulus Therapeutics RNA Therapeutics and Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 132. Regulus Therapeutics Main Business
Table 133. Regulus Therapeutics Latest Developments
Table 134. Roche Basic Information, RNA Therapeutics and Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 135. Roche RNA Therapeutics and Vaccines Product Portfolios and Specifications
Table 136. Roche RNA Therapeutics and Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 137. Roche Main Business
Table 138. Roche Latest Developments
Table 139. AstraZeneca Basic Information, RNA Therapeutics and Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 140. AstraZeneca RNA Therapeutics and Vaccines Product Portfolios and Specifications
Table 141. AstraZeneca RNA Therapeutics and Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 142. AstraZeneca Main Business
Table 143. AstraZeneca Latest Developments
Table 144. Sarepta Therapeutics Basic Information, RNA Therapeutics and Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 145. Sarepta Therapeutics RNA Therapeutics and Vaccines Product Portfolios and Specifications
Table 146. Sarepta Therapeutics RNA Therapeutics and Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 147. Sarepta Therapeutics Main Business
Table 148. Sarepta Therapeutics Latest Developments
Table 149. Orna Therapeutics Basic Information, RNA Therapeutics and Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 150. Orna Therapeutics RNA Therapeutics and Vaccines Product Portfolios and Specifications
Table 151. Orna Therapeutics RNA Therapeutics and Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 152. Orna Therapeutics Main Business
Table 153. Orna Therapeutics Latest Developments
Table 1. RNA Therapeutics and Vaccines Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. RNA Therapeutics and Vaccines Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of mRNA (messenger RNA) Therapeutics
Table 4. Major Players of siRNA (small interfering RNA) Therapeutics
Table 5. Major Players of Antisense Oligonucleotide Therapeutics
Table 6. Global RNA Therapeutics and Vaccines Sales by Type (2018-2023) & (K Units)
Table 7. Global RNA Therapeutics and Vaccines Sales Market Share by Type (2018-2023)
Table 8. Global RNA Therapeutics and Vaccines Revenue by Type (2018-2023) & ($ million)
Table 9. Global RNA Therapeutics and Vaccines Revenue Market Share by Type (2018-2023)
Table 10. Global RNA Therapeutics and Vaccines Sale Price by Type (2018-2023) & (US$/Unit)
Table 11. Global RNA Therapeutics and Vaccines Sales by Application (2018-2023) & (K Units)
Table 12. Global RNA Therapeutics and Vaccines Sales Market Share by Application (2018-2023)
Table 13. Global RNA Therapeutics and Vaccines Revenue by Application (2018-2023)
Table 14. Global RNA Therapeutics and Vaccines Revenue Market Share by Application (2018-2023)
Table 15. Global RNA Therapeutics and Vaccines Sale Price by Application (2018-2023) & (US$/Unit)
Table 16. Global RNA Therapeutics and Vaccines Sales by Company (2018-2023) & (K Units)
Table 17. Global RNA Therapeutics and Vaccines Sales Market Share by Company (2018-2023)
Table 18. Global RNA Therapeutics and Vaccines Revenue by Company (2018-2023) ($ Millions)
Table 19. Global RNA Therapeutics and Vaccines Revenue Market Share by Company (2018-2023)
Table 20. Global RNA Therapeutics and Vaccines Sale Price by Company (2018-2023) & (US$/Unit)
Table 21. Key Manufacturers RNA Therapeutics and Vaccines Producing Area Distribution and Sales Area
Table 22. Players RNA Therapeutics and Vaccines Products Offered
Table 23. RNA Therapeutics and Vaccines Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 24. New Products and Potential Entrants
Table 25. Mergers & Acquisitions, Expansion
Table 26. Global RNA Therapeutics and Vaccines Sales by Geographic Region (2018-2023) & (K Units)
Table 27. Global RNA Therapeutics and Vaccines Sales Market Share Geographic Region (2018-2023)
Table 28. Global RNA Therapeutics and Vaccines Revenue by Geographic Region (2018-2023) & ($ millions)
Table 29. Global RNA Therapeutics and Vaccines Revenue Market Share by Geographic Region (2018-2023)
Table 30. Global RNA Therapeutics and Vaccines Sales by Country/Region (2018-2023) & (K Units)
Table 31. Global RNA Therapeutics and Vaccines Sales Market Share by Country/Region (2018-2023)
Table 32. Global RNA Therapeutics and Vaccines Revenue by Country/Region (2018-2023) & ($ millions)
Table 33. Global RNA Therapeutics and Vaccines Revenue Market Share by Country/Region (2018-2023)
Table 34. Americas RNA Therapeutics and Vaccines Sales by Country (2018-2023) & (K Units)
Table 35. Americas RNA Therapeutics and Vaccines Sales Market Share by Country (2018-2023)
Table 36. Americas RNA Therapeutics and Vaccines Revenue by Country (2018-2023) & ($ Millions)
Table 37. Americas RNA Therapeutics and Vaccines Revenue Market Share by Country (2018-2023)
Table 38. Americas RNA Therapeutics and Vaccines Sales by Type (2018-2023) & (K Units)
Table 39. Americas RNA Therapeutics and Vaccines Sales by Application (2018-2023) & (K Units)
Table 40. APAC RNA Therapeutics and Vaccines Sales by Region (2018-2023) & (K Units)
Table 41. APAC RNA Therapeutics and Vaccines Sales Market Share by Region (2018-2023)
Table 42. APAC RNA Therapeutics and Vaccines Revenue by Region (2018-2023) & ($ Millions)
Table 43. APAC RNA Therapeutics and Vaccines Revenue Market Share by Region (2018-2023)
Table 44. APAC RNA Therapeutics and Vaccines Sales by Type (2018-2023) & (K Units)
Table 45. APAC RNA Therapeutics and Vaccines Sales by Application (2018-2023) & (K Units)
Table 46. Europe RNA Therapeutics and Vaccines Sales by Country (2018-2023) & (K Units)
Table 47. Europe RNA Therapeutics and Vaccines Sales Market Share by Country (2018-2023)
Table 48. Europe RNA Therapeutics and Vaccines Revenue by Country (2018-2023) & ($ Millions)
Table 49. Europe RNA Therapeutics and Vaccines Revenue Market Share by Country (2018-2023)
Table 50. Europe RNA Therapeutics and Vaccines Sales by Type (2018-2023) & (K Units)
Table 51. Europe RNA Therapeutics and Vaccines Sales by Application (2018-2023) & (K Units)
Table 52. Middle East & Africa RNA Therapeutics and Vaccines Sales by Country (2018-2023) & (K Units)
Table 53. Middle East & Africa RNA Therapeutics and Vaccines Sales Market Share by Country (2018-2023)
Table 54. Middle East & Africa RNA Therapeutics and Vaccines Revenue by Country (2018-2023) & ($ Millions)
Table 55. Middle East & Africa RNA Therapeutics and Vaccines Revenue Market Share by Country (2018-2023)
Table 56. Middle East & Africa RNA Therapeutics and Vaccines Sales by Type (2018-2023) & (K Units)
Table 57. Middle East & Africa RNA Therapeutics and Vaccines Sales by Application (2018-2023) & (K Units)
Table 58. Key Market Drivers & Growth Opportunities of RNA Therapeutics and Vaccines
Table 59. Key Market Challenges & Risks of RNA Therapeutics and Vaccines
Table 60. Key Industry Trends of RNA Therapeutics and Vaccines
Table 61. RNA Therapeutics and Vaccines Raw Material
Table 62. Key Suppliers of Raw Materials
Table 63. RNA Therapeutics and Vaccines Distributors List
Table 64. RNA Therapeutics and Vaccines Customer List
Table 65. Global RNA Therapeutics and Vaccines Sales Forecast by Region (2024-2029) & (K Units)
Table 66. Global RNA Therapeutics and Vaccines Revenue Forecast by Region (2024-2029) & ($ millions)
Table 67. Americas RNA Therapeutics and Vaccines Sales Forecast by Country (2024-2029) & (K Units)
Table 68. Americas RNA Therapeutics and Vaccines Revenue Forecast by Country (2024-2029) & ($ millions)
Table 69. APAC RNA Therapeutics and Vaccines Sales Forecast by Region (2024-2029) & (K Units)
Table 70. APAC RNA Therapeutics and Vaccines Revenue Forecast by Region (2024-2029) & ($ millions)
Table 71. Europe RNA Therapeutics and Vaccines Sales Forecast by Country (2024-2029) & (K Units)
Table 72. Europe RNA Therapeutics and Vaccines Revenue Forecast by Country (2024-2029) & ($ millions)
Table 73. Middle East & Africa RNA Therapeutics and Vaccines Sales Forecast by Country (2024-2029) & (K Units)
Table 74. Middle East & Africa RNA Therapeutics and Vaccines Revenue Forecast by Country (2024-2029) & ($ millions)
Table 75. Global RNA Therapeutics and Vaccines Sales Forecast by Type (2024-2029) & (K Units)
Table 76. Global RNA Therapeutics and Vaccines Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 77. Global RNA Therapeutics and Vaccines Sales Forecast by Application (2024-2029) & (K Units)
Table 78. Global RNA Therapeutics and Vaccines Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 79. Moderna Basic Information, RNA Therapeutics and Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 80. Moderna RNA Therapeutics and Vaccines Product Portfolios and Specifications
Table 81. Moderna RNA Therapeutics and Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 82. Moderna Main Business
Table 83. Moderna Latest Developments
Table 84. BioNTech (Pfizer) Basic Information, RNA Therapeutics and Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 85. BioNTech (Pfizer) RNA Therapeutics and Vaccines Product Portfolios and Specifications
Table 86. BioNTech (Pfizer) RNA Therapeutics and Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 87. BioNTech (Pfizer) Main Business
Table 88. BioNTech (Pfizer) Latest Developments
Table 89. Sanofi Basic Information, RNA Therapeutics and Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 90. Sanofi RNA Therapeutics and Vaccines Product Portfolios and Specifications
Table 91. Sanofi RNA Therapeutics and Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 92. Sanofi Main Business
Table 93. Sanofi Latest Developments
Table 94. Novartis Basic Information, RNA Therapeutics and Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 95. Novartis RNA Therapeutics and Vaccines Product Portfolios and Specifications
Table 96. Novartis RNA Therapeutics and Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 97. Novartis Main Business
Table 98. Novartis Latest Developments
Table 99. CureVac Basic Information, RNA Therapeutics and Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 100. CureVac RNA Therapeutics and Vaccines Product Portfolios and Specifications
Table 101. CureVac RNA Therapeutics and Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 102. CureVac Main Business
Table 103. CureVac Latest Developments
Table 104. CSL Basic Information, RNA Therapeutics and Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 105. CSL RNA Therapeutics and Vaccines Product Portfolios and Specifications
Table 106. CSL RNA Therapeutics and Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 107. CSL Main Business
Table 108. CSL Latest Developments
Table 109. Arrowhead Pharmaceuticals Basic Information, RNA Therapeutics and Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 110. Arrowhead Pharmaceuticals RNA Therapeutics and Vaccines Product Portfolios and Specifications
Table 111. Arrowhead Pharmaceuticals RNA Therapeutics and Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 112. Arrowhead Pharmaceuticals Main Business
Table 113. Arrowhead Pharmaceuticals Latest Developments
Table 114. Alnylam Pharmaceuticals Basic Information, RNA Therapeutics and Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 115. Alnylam Pharmaceuticals RNA Therapeutics and Vaccines Product Portfolios and Specifications
Table 116. Alnylam Pharmaceuticals RNA Therapeutics and Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 117. Alnylam Pharmaceuticals Main Business
Table 118. Alnylam Pharmaceuticals Latest Developments
Table 119. GlaxoSmithKline (GSK) Basic Information, RNA Therapeutics and Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 120. GlaxoSmithKline (GSK) RNA Therapeutics and Vaccines Product Portfolios and Specifications
Table 121. GlaxoSmithKline (GSK) RNA Therapeutics and Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 122. GlaxoSmithKline (GSK) Main Business
Table 123. GlaxoSmithKline (GSK) Latest Developments
Table 124. Ionis Pharmaceuticals Basic Information, RNA Therapeutics and Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 125. Ionis Pharmaceuticals RNA Therapeutics and Vaccines Product Portfolios and Specifications
Table 126. Ionis Pharmaceuticals RNA Therapeutics and Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 127. Ionis Pharmaceuticals Main Business
Table 128. Ionis Pharmaceuticals Latest Developments
Table 129. Regulus Therapeutics Basic Information, RNA Therapeutics and Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 130. Regulus Therapeutics RNA Therapeutics and Vaccines Product Portfolios and Specifications
Table 131. Regulus Therapeutics RNA Therapeutics and Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 132. Regulus Therapeutics Main Business
Table 133. Regulus Therapeutics Latest Developments
Table 134. Roche Basic Information, RNA Therapeutics and Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 135. Roche RNA Therapeutics and Vaccines Product Portfolios and Specifications
Table 136. Roche RNA Therapeutics and Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 137. Roche Main Business
Table 138. Roche Latest Developments
Table 139. AstraZeneca Basic Information, RNA Therapeutics and Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 140. AstraZeneca RNA Therapeutics and Vaccines Product Portfolios and Specifications
Table 141. AstraZeneca RNA Therapeutics and Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 142. AstraZeneca Main Business
Table 143. AstraZeneca Latest Developments
Table 144. Sarepta Therapeutics Basic Information, RNA Therapeutics and Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 145. Sarepta Therapeutics RNA Therapeutics and Vaccines Product Portfolios and Specifications
Table 146. Sarepta Therapeutics RNA Therapeutics and Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 147. Sarepta Therapeutics Main Business
Table 148. Sarepta Therapeutics Latest Developments
Table 149. Orna Therapeutics Basic Information, RNA Therapeutics and Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 150. Orna Therapeutics RNA Therapeutics and Vaccines Product Portfolios and Specifications
Table 151. Orna Therapeutics RNA Therapeutics and Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 152. Orna Therapeutics Main Business
Table 153. Orna Therapeutics Latest Developments
LIST OF FIGURES
Figure 1. Picture of RNA Therapeutics and Vaccines
Figure 2. RNA Therapeutics and Vaccines Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global RNA Therapeutics and Vaccines Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global RNA Therapeutics and Vaccines Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. RNA Therapeutics and Vaccines Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of mRNA (messenger RNA) Therapeutics
Figure 10. Product Picture of siRNA (small interfering RNA) Therapeutics
Figure 11. Product Picture of Antisense Oligonucleotide Therapeutics
Figure 12. Global RNA Therapeutics and Vaccines Sales Market Share by Type in 2022
Figure 13. Global RNA Therapeutics and Vaccines Revenue Market Share by Type (2018-2023)
Figure 14. RNA Therapeutics and Vaccines Consumed in Hospitals
Figure 15. Global RNA Therapeutics and Vaccines Market: Hospitals (2018-2023) & (K Units)
Figure 16. RNA Therapeutics and Vaccines Consumed in Research Institutions
Figure 17. Global RNA Therapeutics and Vaccines Market: Research Institutions (2018-2023) & (K Units)
Figure 18. Global RNA Therapeutics and Vaccines Sales Market Share by Application (2022)
Figure 19. Global RNA Therapeutics and Vaccines Revenue Market Share by Application in 2022
Figure 20. RNA Therapeutics and Vaccines Sales Market by Company in 2022 (K Units)
Figure 21. Global RNA Therapeutics and Vaccines Sales Market Share by Company in 2022
Figure 22. RNA Therapeutics and Vaccines Revenue Market by Company in 2022 ($ Million)
Figure 23. Global RNA Therapeutics and Vaccines Revenue Market Share by Company in 2022
Figure 24. Global RNA Therapeutics and Vaccines Sales Market Share by Geographic Region (2018-2023)
Figure 25. Global RNA Therapeutics and Vaccines Revenue Market Share by Geographic Region in 2022
Figure 26. Americas RNA Therapeutics and Vaccines Sales 2018-2023 (K Units)
Figure 27. Americas RNA Therapeutics and Vaccines Revenue 2018-2023 ($ Millions)
Figure 28. APAC RNA Therapeutics and Vaccines Sales 2018-2023 (K Units)
Figure 29. APAC RNA Therapeutics and Vaccines Revenue 2018-2023 ($ Millions)
Figure 30. Europe RNA Therapeutics and Vaccines Sales 2018-2023 (K Units)
Figure 31. Europe RNA Therapeutics and Vaccines Revenue 2018-2023 ($ Millions)
Figure 32. Middle East & Africa RNA Therapeutics and Vaccines Sales 2018-2023 (K Units)
Figure 33. Middle East & Africa RNA Therapeutics and Vaccines Revenue 2018-2023 ($ Millions)
Figure 34. Americas RNA Therapeutics and Vaccines Sales Market Share by Country in 2022
Figure 35. Americas RNA Therapeutics and Vaccines Revenue Market Share by Country in 2022
Figure 36. Americas RNA Therapeutics and Vaccines Sales Market Share by Type (2018-2023)
Figure 37. Americas RNA Therapeutics and Vaccines Sales Market Share by Application (2018-2023)
Figure 38. United States RNA Therapeutics and Vaccines Revenue Growth 2018-2023 ($ Millions)
Figure 39. Canada RNA Therapeutics and Vaccines Revenue Growth 2018-2023 ($ Millions)
Figure 40. Mexico RNA Therapeutics and Vaccines Revenue Growth 2018-2023 ($ Millions)
Figure 41. Brazil RNA Therapeutics and Vaccines Revenue Growth 2018-2023 ($ Millions)
Figure 42. APAC RNA Therapeutics and Vaccines Sales Market Share by Region in 2022
Figure 43. APAC RNA Therapeutics and Vaccines Revenue Market Share by Regions in 2022
Figure 44. APAC RNA Therapeutics and Vaccines Sales Market Share by Type (2018-2023)
Figure 45. APAC RNA Therapeutics and Vaccines Sales Market Share by Application (2018-2023)
Figure 46. China RNA Therapeutics and Vaccines Revenue Growth 2018-2023 ($ Millions)
Figure 47. Japan RNA Therapeutics and Vaccines Revenue Growth 2018-2023 ($ Millions)
Figure 48. South Korea RNA Therapeutics and Vaccines Revenue Growth 2018-2023 ($ Millions)
Figure 49. Southeast Asia RNA Therapeutics and Vaccines Revenue Growth 2018-2023 ($ Millions)
Figure 50. India RNA Therapeutics and Vaccines Revenue Growth 2018-2023 ($ Millions)
Figure 51. Australia RNA Therapeutics and Vaccines Revenue Growth 2018-2023 ($ Millions)
Figure 52. China Taiwan RNA Therapeutics and Vaccines Revenue Growth 2018-2023 ($ Millions)
Figure 53. Europe RNA Therapeutics and Vaccines Sales Market Share by Country in 2022
Figure 54. Europe RNA Therapeutics and Vaccines Revenue Market Share by Country in 2022
Figure 55. Europe RNA Therapeutics and Vaccines Sales Market Share by Type (2018-2023)
Figure 56. Europe RNA Therapeutics and Vaccines Sales Market Share by Application (2018-2023)
Figure 57. Germany RNA Therapeutics and Vaccines Revenue Growth 2018-2023 ($ Millions)
Figure 58. France RNA Therapeutics and Vaccines Revenue Growth 2018-2023 ($ Millions)
Figure 59. UK RNA Therapeutics and Vaccines Revenue Growth 2018-2023 ($ Millions)
Figure 60. Italy RNA Therapeutics and Vaccines Revenue Growth 2018-2023 ($ Millions)
Figure 61. Russia RNA Therapeutics and Vaccines Revenue Growth 2018-2023 ($ Millions)
Figure 62. Middle East & Africa RNA Therapeutics and Vaccines Sales Market Share by Country in 2022
Figure 63. Middle East & Africa RNA Therapeutics and Vaccines Revenue Market Share by Country in 2022
Figure 64. Middle East & Africa RNA Therapeutics and Vaccines Sales Market Share by Type (2018-2023)
Figure 65. Middle East & Africa RNA Therapeutics and Vaccines Sales Market Share by Application (2018-2023)
Figure 66. Egypt RNA Therapeutics and Vaccines Revenue Growth 2018-2023 ($ Millions)
Figure 67. South Africa RNA Therapeutics and Vaccines Revenue Growth 2018-2023 ($ Millions)
Figure 68. Israel RNA Therapeutics and Vaccines Revenue Growth 2018-2023 ($ Millions)
Figure 69. Turkey RNA Therapeutics and Vaccines Revenue Growth 2018-2023 ($ Millions)
Figure 70. GCC Country RNA Therapeutics and Vaccines Revenue Growth 2018-2023 ($ Millions)
Figure 71. Manufacturing Cost Structure Analysis of RNA Therapeutics and Vaccines in 2022
Figure 72. Manufacturing Process Analysis of RNA Therapeutics and Vaccines
Figure 73. Industry Chain Structure of RNA Therapeutics and Vaccines
Figure 74. Channels of Distribution
Figure 75. Global RNA Therapeutics and Vaccines Sales Market Forecast by Region (2024-2029)
Figure 76. Global RNA Therapeutics and Vaccines Revenue Market Share Forecast by Region (2024-2029)
Figure 77. Global RNA Therapeutics and Vaccines Sales Market Share Forecast by Type (2024-2029)
Figure 78. Global RNA Therapeutics and Vaccines Revenue Market Share Forecast by Type (2024-2029)
Figure 79. Global RNA Therapeutics and Vaccines Sales Market Share Forecast by Application (2024-2029)
Figure 80. Global RNA Therapeutics and Vaccines Revenue Market Share Forecast by Application (2024-2029)
Figure 1. Picture of RNA Therapeutics and Vaccines
Figure 2. RNA Therapeutics and Vaccines Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global RNA Therapeutics and Vaccines Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global RNA Therapeutics and Vaccines Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. RNA Therapeutics and Vaccines Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of mRNA (messenger RNA) Therapeutics
Figure 10. Product Picture of siRNA (small interfering RNA) Therapeutics
Figure 11. Product Picture of Antisense Oligonucleotide Therapeutics
Figure 12. Global RNA Therapeutics and Vaccines Sales Market Share by Type in 2022
Figure 13. Global RNA Therapeutics and Vaccines Revenue Market Share by Type (2018-2023)
Figure 14. RNA Therapeutics and Vaccines Consumed in Hospitals
Figure 15. Global RNA Therapeutics and Vaccines Market: Hospitals (2018-2023) & (K Units)
Figure 16. RNA Therapeutics and Vaccines Consumed in Research Institutions
Figure 17. Global RNA Therapeutics and Vaccines Market: Research Institutions (2018-2023) & (K Units)
Figure 18. Global RNA Therapeutics and Vaccines Sales Market Share by Application (2022)
Figure 19. Global RNA Therapeutics and Vaccines Revenue Market Share by Application in 2022
Figure 20. RNA Therapeutics and Vaccines Sales Market by Company in 2022 (K Units)
Figure 21. Global RNA Therapeutics and Vaccines Sales Market Share by Company in 2022
Figure 22. RNA Therapeutics and Vaccines Revenue Market by Company in 2022 ($ Million)
Figure 23. Global RNA Therapeutics and Vaccines Revenue Market Share by Company in 2022
Figure 24. Global RNA Therapeutics and Vaccines Sales Market Share by Geographic Region (2018-2023)
Figure 25. Global RNA Therapeutics and Vaccines Revenue Market Share by Geographic Region in 2022
Figure 26. Americas RNA Therapeutics and Vaccines Sales 2018-2023 (K Units)
Figure 27. Americas RNA Therapeutics and Vaccines Revenue 2018-2023 ($ Millions)
Figure 28. APAC RNA Therapeutics and Vaccines Sales 2018-2023 (K Units)
Figure 29. APAC RNA Therapeutics and Vaccines Revenue 2018-2023 ($ Millions)
Figure 30. Europe RNA Therapeutics and Vaccines Sales 2018-2023 (K Units)
Figure 31. Europe RNA Therapeutics and Vaccines Revenue 2018-2023 ($ Millions)
Figure 32. Middle East & Africa RNA Therapeutics and Vaccines Sales 2018-2023 (K Units)
Figure 33. Middle East & Africa RNA Therapeutics and Vaccines Revenue 2018-2023 ($ Millions)
Figure 34. Americas RNA Therapeutics and Vaccines Sales Market Share by Country in 2022
Figure 35. Americas RNA Therapeutics and Vaccines Revenue Market Share by Country in 2022
Figure 36. Americas RNA Therapeutics and Vaccines Sales Market Share by Type (2018-2023)
Figure 37. Americas RNA Therapeutics and Vaccines Sales Market Share by Application (2018-2023)
Figure 38. United States RNA Therapeutics and Vaccines Revenue Growth 2018-2023 ($ Millions)
Figure 39. Canada RNA Therapeutics and Vaccines Revenue Growth 2018-2023 ($ Millions)
Figure 40. Mexico RNA Therapeutics and Vaccines Revenue Growth 2018-2023 ($ Millions)
Figure 41. Brazil RNA Therapeutics and Vaccines Revenue Growth 2018-2023 ($ Millions)
Figure 42. APAC RNA Therapeutics and Vaccines Sales Market Share by Region in 2022
Figure 43. APAC RNA Therapeutics and Vaccines Revenue Market Share by Regions in 2022
Figure 44. APAC RNA Therapeutics and Vaccines Sales Market Share by Type (2018-2023)
Figure 45. APAC RNA Therapeutics and Vaccines Sales Market Share by Application (2018-2023)
Figure 46. China RNA Therapeutics and Vaccines Revenue Growth 2018-2023 ($ Millions)
Figure 47. Japan RNA Therapeutics and Vaccines Revenue Growth 2018-2023 ($ Millions)
Figure 48. South Korea RNA Therapeutics and Vaccines Revenue Growth 2018-2023 ($ Millions)
Figure 49. Southeast Asia RNA Therapeutics and Vaccines Revenue Growth 2018-2023 ($ Millions)
Figure 50. India RNA Therapeutics and Vaccines Revenue Growth 2018-2023 ($ Millions)
Figure 51. Australia RNA Therapeutics and Vaccines Revenue Growth 2018-2023 ($ Millions)
Figure 52. China Taiwan RNA Therapeutics and Vaccines Revenue Growth 2018-2023 ($ Millions)
Figure 53. Europe RNA Therapeutics and Vaccines Sales Market Share by Country in 2022
Figure 54. Europe RNA Therapeutics and Vaccines Revenue Market Share by Country in 2022
Figure 55. Europe RNA Therapeutics and Vaccines Sales Market Share by Type (2018-2023)
Figure 56. Europe RNA Therapeutics and Vaccines Sales Market Share by Application (2018-2023)
Figure 57. Germany RNA Therapeutics and Vaccines Revenue Growth 2018-2023 ($ Millions)
Figure 58. France RNA Therapeutics and Vaccines Revenue Growth 2018-2023 ($ Millions)
Figure 59. UK RNA Therapeutics and Vaccines Revenue Growth 2018-2023 ($ Millions)
Figure 60. Italy RNA Therapeutics and Vaccines Revenue Growth 2018-2023 ($ Millions)
Figure 61. Russia RNA Therapeutics and Vaccines Revenue Growth 2018-2023 ($ Millions)
Figure 62. Middle East & Africa RNA Therapeutics and Vaccines Sales Market Share by Country in 2022
Figure 63. Middle East & Africa RNA Therapeutics and Vaccines Revenue Market Share by Country in 2022
Figure 64. Middle East & Africa RNA Therapeutics and Vaccines Sales Market Share by Type (2018-2023)
Figure 65. Middle East & Africa RNA Therapeutics and Vaccines Sales Market Share by Application (2018-2023)
Figure 66. Egypt RNA Therapeutics and Vaccines Revenue Growth 2018-2023 ($ Millions)
Figure 67. South Africa RNA Therapeutics and Vaccines Revenue Growth 2018-2023 ($ Millions)
Figure 68. Israel RNA Therapeutics and Vaccines Revenue Growth 2018-2023 ($ Millions)
Figure 69. Turkey RNA Therapeutics and Vaccines Revenue Growth 2018-2023 ($ Millions)
Figure 70. GCC Country RNA Therapeutics and Vaccines Revenue Growth 2018-2023 ($ Millions)
Figure 71. Manufacturing Cost Structure Analysis of RNA Therapeutics and Vaccines in 2022
Figure 72. Manufacturing Process Analysis of RNA Therapeutics and Vaccines
Figure 73. Industry Chain Structure of RNA Therapeutics and Vaccines
Figure 74. Channels of Distribution
Figure 75. Global RNA Therapeutics and Vaccines Sales Market Forecast by Region (2024-2029)
Figure 76. Global RNA Therapeutics and Vaccines Revenue Market Share Forecast by Region (2024-2029)
Figure 77. Global RNA Therapeutics and Vaccines Sales Market Share Forecast by Type (2024-2029)
Figure 78. Global RNA Therapeutics and Vaccines Revenue Market Share Forecast by Type (2024-2029)
Figure 79. Global RNA Therapeutics and Vaccines Sales Market Share Forecast by Application (2024-2029)
Figure 80. Global RNA Therapeutics and Vaccines Revenue Market Share Forecast by Application (2024-2029)
